Longitudinal Studies of Brain Structure and Function in MPS Disorders
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01870375|
Recruitment Status : Recruiting
First Posted : June 6, 2013
Last Update Posted : December 13, 2018
|Condition or disease|
|Mucopolysaccharidosis Type I Mucopolysaccharidosis Type II Mucopolysaccharidosis Type VI Mucopolysaccharidosis Type IV Mucopolysaccharidosis Type VII|
The mucopolysaccharidoses (MPS diseases) are lysosomal disorders (inborn errors of metabolism) that progressively affect most organ systems in the body, usually beginning in childhood. Recent treatment advances have produced amelioration of some of these malfunctions, but notably brain and bone have been difficult to effectively treat. This research addresses the brain abnormalities in the MPS disorders, about which little is known.
The objectives of this research are:
- to identify abnormalities of central nervous system (CNS) structure and function as well as to measure quality-of-life (QOL) in both treated and untreated MPS patients over time. The investigators will accomplish this through longitudinal studies of enrolled patients in designated centers in North America.
- to develop quantitative measurements of change, including direct measurement of neuropsychological function; surrogate MRI markers; and biomarkers to measure stage of disease and treatment outcomes.
- to examine the degree to which independent variables have an impact on both functional and structural outcome. Independent variables may include, but are not limited to: age at first treatment, severity of disease, types of medical abnormalities, nature of genetic mutation, medical events, and sensory abnormalities.
- to examine how treatments such as Enzyme Replacement Therapy (ERT), Hematopoietic Cell Transplant (HCT), substrate reduction, and other palliative and rehabilitative therapies differentially affect CNS structure and function, as well as the subject's quality of life.
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Longitudinal Studies of Brain Structure and Function in MPS Disorders|
|Actual Study Start Date :||September 2009|
|Estimated Primary Completion Date :||August 2019|
|Estimated Study Completion Date :||August 2019|
MPS IH, MPS IHS, MPS IS
MPS IH (Hurler syndrome) patients; MPS IHS (Hurler-Scheie syndrome) patients; and MPS IS (Scheie syndrome) patients
Hunter syndrome patients
Morquio syndrome patients who will be considered for enrollment in the study on an individual basis
Maroteaux-Lamy syndrome patients
Sly syndrome patients who will be considered for enrollment in the study on an individual basis
- Change in Cognitive Ability (IQ) [ Time Frame: Baseline, Year 1, Year 2, Year 3 ]Age-appropriate IQ tests will be administered at baseline and during subject's annual visit.
- Change in Quality of Life [ Time Frame: Baseline, Year 1, Year 2, Year 3 ]Age-appropriate Quality of Life measures will be administered at baseline and during subject's annual visit.
- Change in Neuropsychological Status [ Time Frame: Baseline, Year 1, Year 2, Year 3 ]Memory, Attention, Visual Spatial, and Visual Motor functions will be assessed with age-appropriate measures administered at baseline and during subject's annual visit.
- Change in Emotional and Behavioral Health [ Time Frame: Baseline, Year 1, Year 2, Year 3 ]Age-appropriate measures of emotional and behavioral health will be administered at baseline and during subject's annual visit.
- Change Shown in Magnetic Resonance Imaging of the Brain [ Time Frame: Baseline, Year 1, Year 2, Year 3 ]Magnetic resonance imaging of each subject's brain will be performed at baseline and during subject's annual visit to acquire volumetric, diffusion tensor imaging (DTI), and resting state data. These data will be analyzed to identify any changes occurring over time.
- Change in Adaptive Functions [ Time Frame: Baseline, Year 1, Year 2, Year 3 ]Vineland Adaptive Behavior Scales, a measure of communication, daily living skills, socialization and motor function, will be administered at baseline and during subject's annual visit.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01870375
|Contact: Ashley Schneideremail@example.com|
|United States, California|
|Oakland Children's Hospital||Recruiting|
|Oakland, California, United States, 94609|
|Contact: Jo Ann Johnson 510-428-3885 ext 5421 JAJohnson@mail.cho.org|
|Principal Investigator: Paul Harmatz, M.D.|
|United States, Minnesota|
|University of Minnesota||Enrolling by invitation|
|Minneapolis, Minnesota, United States, 55455|
|United States, New York|
|New York University||Recruiting|
|New York, New York, United States, 10016|
|Contact: Michele Ford 212-263-6981 firstname.lastname@example.org|
|Principal Investigator: Heather Lau, M.D.|
|Hospital for Sick Children||Recruiting|
|Toronto, Ontario, Canada, M5G1X8|
|Contact: Nirosha Srimathan 416-813-7654 ext 202639 email@example.com|
|Principal Investigator: Michal Inbar-Feigenberg, M.D.|
|Principal Investigator:||Chester B. Whitley, M.D., Ph.D.||University of Minnesota - Clinical and Translational Science Institute|
|Study Director:||Ashley Schneider||University of Minnesota - Clinical and Translational Science Institute|
|Study Chair:||Paul Harmatz, M.D.||Oakland Children's Hospital|
|Study Chair:||Michal Inbar-Feigenberg, M.D.||Hospital for Sick Children, Toronto, Ontario, CA|
|Study Chair:||Heather Lau, M.D.||New York University|